Today: 11 June 2026
Bank of America stock climbs as 10% credit-card cap talk hits Wall Street
22 January 2026
1 min read

Bank of America stock climbs as 10% credit-card cap talk hits Wall Street

New York, Jan 22, 2026, 12:49 EST — Regular session

  • Shares of Bank of America climbed roughly 2% in early afternoon trading, settling near $53.
  • A report indicates Bank of America and Citigroup are considering new credit cards featuring a 10% interest-rate cap.
  • Traders are focused on Capitol Hill and the Fed’s policy meeting scheduled for Jan. 27–28.

Shares of Bank of America climbed roughly 2% Thursday, pushing the stock to $53.09 by early afternoon. The move came after reports surfaced that the bank, along with Citigroup, is mulling new credit cards with interest rates capped at 10%.

Tensions over consumer-lending rules have been simmering for days, as the White House advocates a one-year cap of 10% on credit-card rates. Banks argue this could tighten access to unsecured credit. “For now, it’s an overhang, but that overhang could clear quickly,” said Brian Jacobsen, chief economic strategist at Annex Wealth Management. Reuters

At the World Economic Forum in Davos, JPMorgan Chase CEO Jamie Dimon slammed the proposal as an “economic disaster,” warning it “would remove credit from 80% of Americans.” Speaking at the same event, Trump announced he’s urging Congress to impose a 10% cap on credit-card interest rates for one year. Reuters

Trump told CNBC he’s gotten calls from credit-card companies and urged them to “give people a break,” though he didn’t specify which firms. Banking groups have pushed back, while some Wall Street analysts note that any cap would need legislation and faces steep hurdles. Reuters

BAC climbed alongside a wider rally that’s helped keep Wall Street close to record highs, following Trump’s softened tariff stance on Europe and fresh data showing solid consumer spending. “It’s the TACO trade follow on from yesterday,” said Dustin Thackeray, head of portfolio management at Crewe Advisors. Reuters

Shares of other major banks also climbed. Citigroup advanced roughly 2.3%, Wells Fargo jumped around 3.3%, and JPMorgan increased by about 1.5%. The Financial Select Sector SPDR Fund meanwhile rose close to 1%.

Investors remain uncertain about the practical implications of the “10%” limit. Since credit cards are unsecured loans, issuers usually charge higher interest to offset default risks. A strict cap might force banks to tighten underwriting, reduce credit limits, or hike fees.

The bigger wildcard remains the policy route. Should Congress drag its feet or weaken the proposal, the rally in bank stocks may quickly unravel. But if a firm cap emerges, the blow to interest income might be more severe than the market currently anticipates.

Markets are awaiting clearer guidance from lawmakers on the potential cap’s design, while turning to the Federal Reserve’s Jan. 27–28 policy meeting for fresh insight on the interest rate outlook for lenders.

Stock Market Today

  • US Stocks Rise on AI Gains as Oil Prices Steady Amid Iran War Concerns
    June 11, 2026, 10:56 AM EDT. US stock indices climbed on Thursday, led by artificial intelligence (AI) stocks driving gains in chipmakers like Marvell Technology (+4.3%) and Intel (+10.4%). The S&P 500 rose 0.6%, with the Nasdaq up 0.8% and the Dow gaining 0.7%. Despite escalating tensions in the Iran war, oil prices held steady, with Brent crude easing 1.1% to $92.08 per barrel and U.S. crude down 0.6% to $89.52. The market showed resilience despite concerns over inflation pressures fueled by higher wholesale prices and renewed geopolitical risks. Oracle fell 10.3% after announcing substantial planned borrowing and equity sales to fund AI investments, reflecting investor caution on aggressive spending amidst uncertainty.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Coinbase stock slips after Base balance glitch; what traders are watching next
Previous Story

Coinbase stock slips after Base balance glitch; what traders are watching next

Silver price today hits fresh record above $96 as dollar slips and Fed meeting looms
Next Story

Silver price today hits fresh record above $96 as dollar slips and Fed meeting looms

Go toTop